Official source
Source domain: pmg.org.za
Collected on 17 June 2026
Always confirm details on the official source before acting.
Read out of this document by Govermate's AI, in its own words. Each one quotes the line it came from — confirm on the official source before acting.
Interim local supply of FMD vaccine via operationalised mid-scale production facility
The ARC has operationalised a mid-scale production facility to produce foot-and-mouth disease vaccine doses locally as an interim supply, supplementing imports.
The document's recorded date is 6 February 2026. Confirm on the official source.
Reference
S RNW207-260318
Opening Date
18 March 2026
Closing Date
6 February 2026
In the short term, following the release of the first batch of 12 900 Multivalent doses on 6 February 2026, the ARC has operationalised a mid-scale production facility capable of producing approximately 20 000 Monovalent doses per week (as of the end of March 2026) to provide an interim local supply.
Long-term planned GMP-compliant, high-containment FMD vaccine production facility (pentavalent capacity)
The ARC has completed the design for a new GMP-compliant, high-containment vaccine production facility intended to produce large quantities of pentavalent doses for vaccinating the national herd and providing surplus for export.
The document's recorded date is 6 February 2026. Confirm on the official source.
For the long term, the ARC has completed the design of a new Good Manufacturing Practice (GMP)-compliant, high-containment vaccine production facility aligned with World Organisation for Animal Health Biosafety Regulatory requirements. The facility has a projected capacity of 20 million pentavalent doses annually, sufficient to vaccinate the national herd and provide surplus for export purposes.
Medium-term scaling to commercial-scale production of FMD vaccine doses
The ARC has invested in a commercial-scale production system to increase foot-and-mouth disease vaccine output to provide a larger supply in the medium term.
The document's recorded date is 6 February 2026. Confirm on the official source.
In the medium term, an investment has been made for a 1 000-litre commercial-scale system to increase the production to approximately 200 000 monovalent doses per week (projected by April 2027),
